
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc. is making strides in the commercialization of its CNSide Diagnostic platform, with expanded manufacturing capacity and enhanced leadership that supports compliance and scalability. The company's collaboration with NCI-Designated Cancer Centers and a favorable policy agreement with UnitedHealthcare bolster its payor coverage and market readiness, indicating strong early adoption prospects. Furthermore, the company secured an $18 million grant from the Cancer Prevention and Research Institute of Texas to advance research on leptomeningeal metastases, reflecting a solid commitment to growth and innovation in its drug development pipeline.
Bears say
Plus Therapeutics Inc faces significant risks that adversely affect its stock outlook, primarily centered around the potential failure of its product candidates to demonstrate safety and efficacy during clinical trials. Furthermore, challenges in obtaining regulatory approval for commercial sale and securing suitable reimbursement could hinder the company's financial viability. Although pro forma EPS reported a net income of $1.2 million, it fell short of estimates and consensus predictions, indicating underlying financial weaknesses that contribute to the negative sentiment surrounding the stock.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares